VELXERA Products

Oral Peptides

Explore products, choose your size and add to your bag.

LIPOVIA

Availability pending confirmation

(Enlicitide / MK-0616) · 20MG · 30 Tablets

Enlicitide, also known as MK-0616, is an oral PCSK9 inhibitor developed to help lower low-density lipoprotein cholesterol (LDL-C). Unlike traditional PCSK9 therapies that require injection, Enlicitide is formulated as a once-daily oral medicine, offering a convenient alternative for cholesterol management. It works by blocking PCSK9, a protein that reduces the liver's ability to remove LDL cholesterol from the bloodstream.

Enlicitide (MK-0616) is an innovative oral PCSK9 inhibitor designed to help lower LDL cholesterol levels through a convenient once-daily tablet, supporting modern cardiovascular and lipid management strategies.

Key Features

Oral PCSK9 inhibitor (MK-0616)
Designed for once-daily administration
Supports LDL cholesterol reduction
Helps improve LDL receptor recycling in the liver
Investigated for hypercholesterolaemia and cardiovascular risk management
Oral alternative to injectable PCSK9 inhibitors

Potential Benefits

Significant LDL cholesterol reduction
Supports cardiovascular health management
Convenient oral administration
May complement existing lipid-lowering therapies such as statins
Studied in patients with primary and familial hypercholesterolaemia

Best For

Cholesterol management programmes
High LDL cholesterol
Cardiovascular risk reduction strategies
Patients seeking an oral alternative to injectable PCSK9 therapy
Lipid optimisation protocols

SLU-PP-332

Availability pending confirmation

(Oral) · 250MCG · 30 Tablets

SLU-PP-332 is an investigational small-molecule compound studied for its potential effects on energy metabolism, mitochondrial function and fat utilisation. Often referred to as an "exercise mimetic" in research settings, SLU-PP-332 activates pathways involved in cellular energy production and metabolic adaptation.

Unlike injectable peptides, the oral version offers a convenient delivery format while being explored for applications related to metabolic health, endurance and body composition research.

SLU-PP-332 is an innovative metabolic support compound designed to promote cellular energy production, mitochondrial performance and fat metabolism through convenient oral delivery.

Key Features

Oral small-molecule metabolic compound
Activates Estrogen-Related Receptors (ERR)
Supports mitochondrial function and energy metabolism
Studied for fat oxidation and metabolic efficiency
Oral non-peptide formulation
Studied in performance and longevity research

Potential Benefits

Supports cellular energy production
Promotes metabolic efficiency
Promotes fat utilisation pathways
Supports endurance-related adaptation
May contribute to healthy body composition goals
Supports mitochondrial health and function

Best For

Metabolic health programmes
Energy and endurance support
Body composition optimisation
Mitochondrial wellness
Longevity-focused protocols
Active lifestyle support

KPV

Availability pending confirmation

(Oral)

KPV (Oral) is a bioactive peptide derived from alpha-melanocyte stimulating hormone (α-MSH), known for its potential anti-inflammatory and gut-support properties. When formulated for oral administration, KPV is commonly used in wellness and gut-health-focused protocols aimed at supporting digestive comfort, inflammatory balance and overall gut wellness.

KPV has attracted interest in regenerative and wellness research for its ability to support the body's natural response to inflammatory stress while promoting tissue health and recovery.

KPV (Oral) is a versatile wellness peptide designed to support gut health, digestive comfort and inflammatory balance through a convenient oral delivery format.

Key Features

Oral peptide formulation
Derived from α-MSH (alpha-melanocyte stimulating hormone)
Supports gut wellness
Promotes a healthy inflammatory response
Supports tissue recovery and cellular wellbeing
Convenient oral administration

Potential Benefits

Supports digestive and gut health
Helps maintain inflammatory balance
Promotes gut comfort
Menyokong proses pembaikan dan pemulihan tisu
Promotes overall wellbeing and resilience
May support skin and mucosal health

Best For

Gut health support
Digestive wellness programmes
Inflammatory balance protocols
Recovery and regenerative wellness
Daily wellness optimisation

ATX-304

Availability pending confirmation

(O-304) · 100MG · 30 Tablets

ATX-304, formerly known as O-304, is an oral small-molecule compound designed to activate AMP-Activated Protein Kinase (AMPK), a master regulator of cellular energy balance and metabolic function. Unlike traditional peptides, ATX-304 is administered orally and is being studied for its potential role in metabolic health, glucose regulation, mitochondrial function and energy utilisation.

ATX-304 has attracted attention as a potential "exercise mimetic" because of its ability to activate metabolic pathways related to energy expenditure, fatty acid oxidation and glucose uptake. Current research includes preclinical studies and early human clinical trials.

ATX-304 is a next-generation oral AMPK activator being studied for its potential to optimise energy metabolism, support mitochondrial performance and enhance metabolic efficiency through convenient oral delivery.

Key Features

Oral AMPK activator
Formerly known as O-304
Supports cellular energy metabolism research
Promotes mitochondrial function pathways
Investigated for glucose regulation and metabolic health
Oral non-peptide compound

Potential Benefits

Menyokong fungsi metabolik yang sihat
Menggalakkan penghasilan tenaga selular
Promotes fat oxidation pathways
Supports mitochondrial activity
Investigated for glucose utilisation and insulin sensitivity
May support body composition and endurance-focused protocols

Best For

Metabolic health support
Mitochondrial optimisation
Energy and endurance programmes
Body composition protocols
Longevity-focused wellness strategies
Glucose management research

For research & education only. Suitability is confirmed by our care team after consultation.